JP2021134211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021134211A5 JP2021134211A5 JP2021023812A JP2021023812A JP2021134211A5 JP 2021134211 A5 JP2021134211 A5 JP 2021134211A5 JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021134211 A5 JP2021134211 A5 JP 2021134211A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- composition according
- tetrahydrospiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- UKBQFBRPXKGJPY-INIZCTEOSA-N 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide Chemical compound C(C)OC=1C(=NC=CC=1)OC=1C=C(C=NC=1)C1=NC=C(C=N1)C(=O)N[C@@H]1COCC1 UKBQFBRPXKGJPY-INIZCTEOSA-N 0.000 claims 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 6
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 4
- 239000005711 Benzoic acid Substances 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 235000010233 benzoic acid Nutrition 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000027032 Renal vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980664P | 2020-02-24 | 2020-02-24 | |
| US62/980664 | 2020-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021134211A JP2021134211A (ja) | 2021-09-13 |
| JP2021134211A5 true JP2021134211A5 (https=) | 2024-01-24 |
Family
ID=74844948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021023812A Pending JP2021134211A (ja) | 2020-02-24 | 2021-02-18 | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12472180B2 (https=) |
| EP (1) | EP4110395A1 (https=) |
| JP (1) | JP2021134211A (https=) |
| AR (1) | AR121400A1 (https=) |
| CA (1) | CA3172765A1 (https=) |
| TW (1) | TW202140004A (https=) |
| WO (1) | WO2021171164A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119219759B (zh) * | 2024-10-22 | 2026-03-27 | 浙江工业大学 | 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3713942T3 (fi) | 2017-11-21 | 2023-05-04 | Pfizer | 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola |
| CR20210110A (es) * | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| WO2020234726A1 (en) * | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2021
- 2021-02-18 JP JP2021023812A patent/JP2021134211A/ja active Pending
- 2021-02-20 TW TW110105906A patent/TW202140004A/zh unknown
- 2021-02-22 WO PCT/IB2021/051479 patent/WO2021171164A1/en not_active Ceased
- 2021-02-22 CA CA3172765A patent/CA3172765A1/en active Pending
- 2021-02-22 US US17/904,537 patent/US12472180B2/en active Active
- 2021-02-22 EP EP21709111.5A patent/EP4110395A1/en active Pending
- 2021-02-23 AR ARP210100459A patent/AR121400A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| KR101699501B1 (ko) | 간기능부전 환자들에 대한 피르페니돈 치료법 | |
| JP2022121594A5 (https=) | ||
| JP2019172692A5 (https=) | ||
| JP2010516759A (ja) | Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドの酢酸塩、その製造方法、及びそれを含む薬剤学的組成物 | |
| JP2019531320A5 (https=) | ||
| JP2021134211A5 (https=) | ||
| KR20150046125A (ko) | Sglt2 저해약과 항고혈압약의 조합 | |
| JP2008512486A5 (https=) | ||
| JP4804353B2 (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
| CN111202731A (zh) | 联合用药应用以及一种药用组合物及其应用 | |
| JP2004505042A (ja) | 糖尿病及びグルコース変性の予防及び／または治療のための方法及び組成物 | |
| JP2019520381A (ja) | 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物 | |
| JP2019518738A (ja) | 組成物、ならびにその適用および薬学的調製の方法 | |
| CN106999458B (zh) | 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物 | |
| CN104945394A (zh) | 二氢嘧啶衍生物的晶型 | |
| TW200409643A (en) | Preventive agents for diabetes mellitus | |
| JP6294665B2 (ja) | スピロケタール誘導体の結晶 | |
| JPWO2023152698A5 (https=) | ||
| JPWO2019201752A5 (https=) | ||
| CN107998385A (zh) | 水蛭素作为防治高尿酸血症药物的用途 | |
| CN101269040A (zh) | 盐酸吡格列酮缓释滴丸及其制备方法 | |
| CN102532122B (zh) | 酒石酸罗格列酮的制备方法 | |
| US10640514B2 (en) | Polymorph of DPPIV inhibitor maleate and preparation method therefor | |
| JP2022541178A (ja) | （ｓ）－３－アミノ－６－メトキシ－ｎ－（３，３，３－トリフルオロ－２－ヒドロキシ－２－メチルプロピル）－５－（トリフルオロメチル）ピコリンアミド製剤 |